Natco Pharma shares jump 1.25% as company announces U.S. launch of generic Carboplatin Injection
Why did Natco Pharma Ltd shares jump today?
Natco Pharma Ltd shares saw a positive movement on Monday, rising 1.25% to trade at ₹795.05 as of 02:38 PM. The stock gained investor attention after the company officially announced the launch of Carboplatin Injection, a generic version of the widely used cancer drug Paraplatin®, in the United States market. The announcement was made through a formal regulatory filing to the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on October 19th, 2026, under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements.
The launch is being carried out by Natco Pharma's U.S.-based subsidiary, NATCO Pharma USA LLC, in a manufacturing collaboration with Teyro Labs Pvt Ltd, a company based in Chennai. This move is particularly significant because it addresses a critical shortage of Carboplatin Injection that has been affecting the U.S. market. Carboplatin Injection is an important chemotherapy medication used in the treatment of advanced ovarian carcinoma. It is prescribed for first-line combination therapy as well as palliative treatment of recurrent disease in patients who have undergone prior chemotherapy, making it a vital drug for cancer patients in the United States.
The market likely reacted positively to this news for several reasons. First, entering the U.S. oncology market through a generic version of a well-established drug like Paraplatin® opens up a substantial revenue opportunity for Natco. Second, the fact that there is an existing shortage of this product in the U.S. means demand is already high, giving Natco a favorable position as one of the suppliers to fill that gap. The collaboration with a domestic manufacturing partner like Teyro Labs also signals a cost-effective approach to production, which could translate into better margins. Overall, investors appear optimistic about the growth potential this launch brings to Natco Pharma's portfolio.
What does Natco Pharma Ltd do?
Natco Pharma Limited, listed on both the Bombay Stock Exchange (Scrip Code: 524816) and the National Stock Exchange of India (Scrip Code: NATCOPHARM), is a pharmaceutical company headquartered at Natco House, Road No. 2, Banjara Hills, Hyderabad, India. The company is involved in the development and commercialization of pharmaceutical products, including generic medicines, and operates through subsidiaries to serve international markets. It maintains a corporate structure that includes a Company Secretary and Compliance Officer who handles regulatory filings and stock exchange communications in accordance with SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.
NATCO Pharma Limited has an established presence in the U.S. pharmaceutical market through its subsidiary NATCO Pharma USA LLC, where it focuses on launching generic versions of branded drugs. A notable example of its market activity is the launch of Carboplatin Injection, a generic version of Paraplatin®, which the company introduced in collaboration with Teyro Labs Pvt Ltd. This highlights NATCO's approach of partnering with other entities to bring affordable generic pharmaceutical products to consumers in the United States and potentially other international markets.
Natco Pharma Ltd Financials
In CroresNatco Pharma Ltd reported revenues of ₹739.1 crores in the March 2026 quarter, followed by ₹735.2 crores in the June 2026 quarter, reflecting a marginal decline of approximately 0.5% quarter-over-quarter, indicating broadly stable top-line performance. On the profitability front, the company earned a net profit of ₹267.9 crores in March 2026, which contracted to ₹206.5 crores in June 2026, representing a notable decline of about 22.9% quarter-over-quarter. While revenues remained relatively flat between the two quarters, the significant drop in profit suggests that operating costs or other expenses may have increased, compressing profit margins despite steady sales. Overall, the data points to consistent revenue generation with a weakening trend in bottom-line profitability.
Natco Pharma Ltd Shareholding Pattern
Promoter holding stands at 49.39% of the total share capital. Foreign Institutional Investors (FIIs) hold 15.99% stake in the company, while Domestic Institutional Investors (DIIs) hold 6.16%. Public shareholders hold the remaining 28.46% stake in Natco Pharma Ltd.
Natco Pharma Ltd FAQs
Q: Why did Natco shares jump 1.25% today?
Natco Pharma announces launch of Carboplatin Injection (generic of Paraplatin) in the U.S. market. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Natco Pharma Ltd?
As per the latest data, promoters hold 49.39% stake in Natco Pharma Ltd, while FII holding stands at 15.99%. Domestic institutional investors hold 6.16%, and public shareholders account for 28.46% of the equity.
Q: What is the current stock price of Natco Pharma Ltd?
Natco Pharma Ltd shares are currently trading at ₹795.05, recording a gain of 1.25% from the previous close.
Q: What is the market capitalization of Natco Pharma Ltd?
The company currently has a market capitalization of ₹14240.13 crore, reflecting its valuation in the Indian equity market.